Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
35 hedge funds and large institutions have $80.5M invested in Avadel Pharmaceuticals in 2013 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 8 increasing their positions, 11 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
39.02% more ownership
Funds ownership: 0% → 39.02% (+39%)
12% more capital invested
Capital invested by funds: $71.8M → $80.5M (+$8.66M)
6% more funds holding
Funds holding: 33 → 35 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
27% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
Bourgeon Capital Management
Darien,
Connecticut
|
+$339K |
| 2 |
Bank of New York Mellon
New York
|
+$330K |
| 3 |
DADC
D.A. Davidson & Co
Great Falls,
Montana
|
+$198K |
| 4 |
IAM
Iridian Asset Management
Westport,
Connecticut
|
+$142K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
+$102K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
Castleark Management
Chicago,
Illinois
|
-$6.83M |
| 2 |
Millennium Management
New York
|
-$585K |
| 3 |
CCI
Columbus Circle Investors
|
-$269K |
| 4 |
Morgan Stanley
New York
|
-$134K |
| 5 |
BWP
Baldwin Wealth Partners
Marion,
Massachusetts
|
-$114K |
AVDL Hedge Fund Activity: Q4 2013 in Review
35 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q4 2013, worth a combined $80.5M — up 12% from $71.8M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new AVDL positions and 3 closed out — a net gain of 3 holders — while 8 added to existing stakes and 11 trimmed.
The largest buyer was Bourgeon Capital Management, opening a new position worth an estimated $339K. The largest seller was Castleark Management, exiting entirely with an estimated $6.83M sold.
- 35 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q4 2013, up from 33 in Q3 2013.
- Funds reported $80.5M of Avadel Pharmaceuticals stock for Q4 2013, up 12% quarter-over-quarter.
- 6 funds opened new Avadel Pharmaceuticals positions in Q4 2013 and 3 closed out, a net change of +3 holders.
- The largest Avadel Pharmaceuticals buyer in Q4 2013 was Bourgeon Capital Management, an estimated $339K added.
- The largest Avadel Pharmaceuticals seller in Q4 2013 was Castleark Management, an estimated $6.83M sold.
Based on aggregated 13F filings for Q4 2013.